Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt 2015 SR
The report covers Gedeon Richter's sustainability performance for 2014-2015, highlighting its transition to GRI G4 guidelines. Key achievements include the FDA approval of cariprazine and the expansion of its biotechnology plant in Debrecen. The company emphasizes its commitment to women's health, R&D investment averaging 10% of sales, and environmental responsibility through its ISO 14001-certified management systems. It also details social initiatives like the Richter Health City and Richter for Women programs.
Company: Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt
Sector: Manufacturing
Country: Hungary
Year: 2015
Type: SR
Pages: 76
Back to company
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt
Sustainability Report
The report covers Gedeon Richter's sustainability performance for 2014-2015, highlighting its transition to GRI G4 guidelines. Key achievements include the FDA approval of cariprazine and the expansion of its biotechnology plant in Debrecen. The company emphasizes its commitment to women's health, R&D investment averaging 10% of sales, and environmental responsibility through its ISO 14001-certified management systems. It also details social initiatives like the Richter Health City and Richter for Women programs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2014 - Dec 31, 2015
Fiscal Year
2015
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees